buprenorphine 12 MG / naloxone 3 MG Sublingual Film [Suboxone]

RxCUI
1307063
RxNorm name
buprenorphine 12 MG / naloxone 3 MG Sublingual Film [Suboxone]
Display name
SUBOXONE (Sublingual)
Full name
buprenorphine 12 MG / naloxone 3 MG Sublingual Film [Suboxone]
Term type
SBD
Status
Active
Strength
12-3 mg
Dose form
Film
Route
Sublingual
Updated
2026-11-19 17:12:33

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
102012
Active start
102012
Multiple ingredient
YES
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
buprenorphine hydrochloride12 MG / 1 EACHbuprenorphinebuprenorphine
naloxone hydrochloride dihydrate3 MG / 1 EACHnaloxonenaloxone

Dose Form Concepts#

Dose form, RxCUI table
Dose formRxCUI
Sublingual Film2269578

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
buprenorphine1819
naloxone7242

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRSuboxone 12/3 Sublingual Film1NAMES
RxNorm Namebuprenorphine 12 MG / naloxone 3 MG Sublingual Film [Suboxone]1NAMES
RxNorm Synonym
2 linked values
2NAMES
TTYSBD1ATTRIBUTES
SPL_SET_ID8a5edcf9-828c-4f97-b671-268ab13a8ecd1CODES
RxCUI13070631CODES
MMSL_CODEBD281141CODES

FDA NDC Products And Packages#

Package NDC, Product NDC, Name table
Package NDCProduct NDCNameLabelerApplication
12496-1212-312496-1212Suboxone buprenorphine hydrochloride, naloxone hydrochlorideINDIVIOR INC.NDA022410

Drugs@FDA Applications#

Application, NDC, Name table
ApplicationNDCNameMarketing categoryLabeler
NDA02241012496-1212Suboxone buprenorphine hydrochloride, naloxone hydrochlorideNDAINDIVIOR INC.

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 2 matching rows.

NDC11, Source, Active table
NDC11SourceActive
12496121201rxnav_ndcsyes
12496121203rxnav_ndcsyes

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
SuboxoneBUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDEINDIVIOR INC.8a5edcf9-828c-4f97-b671-268ab13a8ecd2025-12-22Warnings, Adverse reactionsExact identifier
ndc (package): 12496-1212-3
ndc (product): 12496-1212
ndc11 (package): 12496121201
ndc11 (package): 12496121203
rxcui: 1307063

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
8a5edcf9-828c-4f97-b671-268ab13a8ecdSuboxone 12 MG / 3 MG Sublingual Film [PSN] · buprenorphine 12 MG / naloxone 3 MG Sublingual Film [Suboxone] [SBD] · Suboxone 12/3 (buprenorphine HCl / naloxone HCl dihydrate) Sublingual Film [SY] · Suboxone 12/3 Sublingual Film [SY]437These highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual film. SUBOXONE ® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 200220251222

Recently Linked DailyMed Labels#

Set ID, Title, Manufacturer table
Set IDTitleManufacturerEffective
8a5edcf9-828c-4f97-b671-268ab13a8ecdHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual film. SUBOXONE (buprenorphine and naloxone) sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002INDIVIOR INC. | SGS North America Inc. | Aquestive Therapeutics | Alcami Carolinas Corporation | Infinity Labs IN, Inc | Sharp Packaging Services, LLC | SpecGx LLC | Macfarlan Smith Limited | INDIVIOR UK Limited | Butterworth Laboratories Ltd | QUOTIENT SCIENCES (ALNWICK) LIMITED | Siegfried AG | Veranova, L.P. | PPD Development, L.P.20260108
8a5edcf9-828c-4f97-b671-268ab13a8ecdThese highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual film. SUBOXONE ® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002INDIVIOR INC. | Alcami Carolinas Corporation | Aquestive Therapeutics | Butterworth Laboratories Ltd | INDIVIOR UK Limited | Infinity Labs IN, Inc | Macfarlan Smith Limited | PPD Development, L.P. | QUOTIENT SCIENCES (ALNWICK) LIMITED | SGS North America Inc. | Sharp Packaging Services, LLC | Siegfried AG | SpecGx LLC | Veranova, L.P.20251222
8a5edcf9-828c-4f97-b671-268ab13a8ecdThese highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual film. SUBOXONE ® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002INDIVIOR INC. | Alcami Carolinas Corporation | Aquestive Therapeutics | Butterworth Laboratories Ltd | INDIVIOR UK Limited | Infinity Labs IN, Inc | Macfarlan Smith Limited | PPD Development, L.P. | QUOTIENT SCIENCES (ALNWICK) LIMITED | SGS North America Inc. | Sharp Packaging Services, LLC | Siegfried AG | SpecGx LLC | Veranova, L.P.20251222
16ed4947-fd1b-4fb3-a200-45e93597565bNational Council for Prescription Drug Programs20130213
e2501033-98ae-4ccb-a8fb-a4432a7646b2National Council for Prescription Drug Programs20130213

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCV03ABAntidotesATC1-4naloxone
ATCN07BCDrugs used in opioid dependenceATC1-4buprenorphine
ATCN02AEOripavine derivativesATC1-4buprenorphine
ATCA06AHPeripheral opioid receptor antagonistsATC1-4naloxone
FDASPLN0000175691Opioid AntagonistEPChas_epcnaloxone
FDASPLN0000175689Partial Opioid AgonistEPChas_epcbuprenorphine
FDASPLN0000000154Opioid AntagonistsMOAhas_moanaloxone
FDASPLN0000175685Partial Opioid AgonistsMOAhas_moabuprenorphine
MEDRTD002047BuprenorphineCHEMhas_ingredientbuprenorphine
MEDRTD009270NaloxoneCHEMhas_ingredientnaloxone
MEDRTD004342Drug HypersensitivityDISEASEci_withnaloxone
MEDRTD004342Drug HypersensitivityDISEASEci_withbuprenorphine
MEDRTD006556Heroin DependenceDISEASEmay_treatbuprenorphine
MEDRTD009293Opioid-Related DisordersDISEASEmay_diagnosenaloxone
MEDRTD009293Opioid-Related DisordersDISEASEmay_treatnaloxone
MEDRTD010146PainDISEASEmay_treatbuprenorphine
MEDRTD012120Respiration DisordersDISEASEmay_treatnaloxone
MEDRTD012772Shock, SepticDISEASEmay_treatnaloxone
MEDRTN0000000154Opioid AntagonistsMOAhas_moabuprenorphine
MEDRTN0000000154Opioid AntagonistsMOAhas_moanaloxone
MEDRTN0000175685Partial Opioid AgonistsMOAhas_moabuprenorphine
MEDRTN0000175729Central Nervous System StimulationPEhas_penaloxone
MEDRTN0000008768Decreased Organized Electrical ActivityPEhas_pebuprenorphine
MEDRTN0000178478Increased Blood PressurePEhas_penaloxone
MEDRTN0000009393Increased Medullary Respiratory DrivePEhas_penaloxone

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH12 MG / 3 MG
ATTRIBUTESGENERAL_CARDINALITYMULTI
ATTRIBUTESHUMAN_DRUGUS
ATTRIBUTESRXNAV_HUMAN_DRUGUS
ATTRIBUTESSCHEDULE3
CODESNDANDA022410
NAMESPrescribable SynonymSuboxone 12 MG / 3 MG Sublingual Film
SOURCESSourceGold Standard Alchemy
SOURCESSourceMetathesaurus FDA Structured Product Labels
SOURCESSourceMicromedex RED BOOK
SOURCESSourceMultum MediSource Lexicon